Hyperalgesia and NMDA Receptor Antagonist

NCT ID: NCT02087202

Last Updated: 2014-03-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

NMDA receptor is administered and postoperative remote hyperalgesia is investigated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

NMDA receptor is adminstered and postoperative tertiary hyperalgesia is investigated.

QST and pain measures for remote hyperalgesia are compared between control and magnesium or ketamine group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

magnesium

magnesium is added perioperatively to those patients undergoing staged total knee arthroplasty and other surgeries.

Group Type EXPERIMENTAL

Magnesium Sulfate

Intervention Type DRUG

magnesium sulfate is added to the patients

ketamine

ketamine is administered to those patients undergoing stated TKA and other operations.

Group Type EXPERIMENTAL

ketamine

Intervention Type DRUG

ketamine is added to the patients.

control

normal saline (placebo) is administered to the patients.

Group Type PLACEBO_COMPARATOR

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium Sulfate

magnesium sulfate is added to the patients

Intervention Type DRUG

ketamine

ketamine is added to the patients.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA1-2

Exclusion Criteria

* contraindication to the study drugs
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seoul National University Bundang Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kim Mihyun

clinical professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

hyperalgesia

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Magnesium and Postoperative Pain
NCT03253224 TERMINATED PHASE4